SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

United Therapeutics Corp – ‘8-K’ for 2/10/21

On:  Wednesday, 2/10/21, at 6:01am ET   ·   For:  2/10/21   ·   Accession #:  1104659-21-16929   ·   File #:  0-26301

Previous ‘8-K’:  ‘8-K’ on 2/5/21 for 2/4/21   ·   Next:  ‘8-K’ on / for 2/24/21   ·   Latest:  ‘8-K’ on / for 6/7/21

Magnifying glass tilted right emoji
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/10/21  United Therapeutics Corp          8-K:8,9     2/10/21   11:240K                                   Toppan Merrill/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     29K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     26K 
 7: R1          Cover                                               HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- tm215968d1_8k_htm                   XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- uthr-20210210_lab                     XML     96K 
 5: EX-101.PRE  XBRL Presentations -- uthr-20210210_pre              XML     64K 
 3: EX-101.SCH  XBRL Schema -- uthr-20210210                         XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
11: ZIP         XBRL Zipped Folder -- 0001104659-21-016929-xbrl      Zip     17K 

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0001082554  i false 0001082554 2021-02-10 2021-02-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares










FORM  i 8-K



Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):   i February 10, 2021


 i United Therapeutics Corporation

(Exact Name of Registrant as Specified in its Charter)


 i Delaware    i 000-26301    i 52-1984749
(State or Other   (Commission   (I.R.S. Employer
Jurisdiction of   File Number)   Identification Number)


 i 1040 Spring Street    
 i Silver Spring,  i MD    i 20910
(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: ( i 301)  i 608-9292


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


 i ¨       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


 i ¨       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


 i ¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


 i ¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading symbol(s)   Name of each exchange on which
 i Common Stock, par value $0.01 per share    i UTHR    i Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company       i ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨








Item 8.01. Other Events.


On February 10, 2021, United Therapeutics Corporation issued a press release announcing the commercial launch of the Remunity® Pump for Remodulin®. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.


REMUNITY and REMODULIN are registered trademarks of United Therapeutics Corporation.


Item 9.01. Exhibits


  (d)  Exhibits
  Exhibit No.   Description of Exhibit
  99.1   Press release dated February 10, 2021
  104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL


  C: 2 





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: February 10, 2021 By: /s/ Paul A. Mahon
  Name: Paul A. Mahon
  Title: General Counsel





Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:2/10/21None on these Dates
 List all Filings 
Filing Submission 0001104659-21-016929   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Jun. 14, 8:50:54.0am ET